State of Alaska Department of Revenue Increases Holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART)

State of Alaska Department of Revenue raised its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 55.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 12,623 shares of the life sciences company’s stock after buying an additional 4,494 shares during the quarter. State of Alaska Department of Revenue’s holdings in Integra Lifesciences were worth $758,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Boston Partners increased its stake in shares of Integra Lifesciences by 1.3% in the 2nd quarter. Boston Partners now owns 13,119 shares of the life sciences company’s stock worth $733,000 after purchasing an additional 171 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of Integra Lifesciences by 1.5% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 13,080 shares of the life sciences company’s stock worth $731,000 after purchasing an additional 190 shares in the last quarter. Zions Bancorporation N.A. increased its stake in shares of Integra Lifesciences by 5.9% in the 2nd quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock worth $243,000 after purchasing an additional 242 shares in the last quarter. LPL Financial LLC increased its stake in shares of Integra Lifesciences by 4.4% in the 2nd quarter. LPL Financial LLC now owns 5,754 shares of the life sciences company’s stock worth $319,000 after purchasing an additional 242 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its stake in shares of Integra Lifesciences by 1.4% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 28,654 shares of the life sciences company’s stock worth $1,600,000 after purchasing an additional 404 shares in the last quarter. Institutional investors and hedge funds own 81.93% of the company’s stock.

Several equities research analysts have recently commented on IART shares. ValuEngine lowered Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. BTIG Research set a $70.00 price objective on Integra Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, July 24th. JMP Securities upped their price objective on Integra Lifesciences to $75.00 in a research note on Thursday, July 25th. Wells Fargo & Co reduced their price objective on Integra Lifesciences from $68.00 to $65.00 and set a “market perform” rating for the company in a research note on Tuesday, October 8th. Finally, Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 price objective for the company in a research note on Monday, September 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $62.42.

Shares of Integra Lifesciences stock opened at $61.85 on Wednesday. The company has a market capitalization of $5.20 billion, a P/E ratio of 23.22, a P/E/G ratio of 1.88 and a beta of 1.10. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76. The company has a fifty day moving average of $60.28 and a 200 day moving average of $55.87. Integra Lifesciences Holdings Corp has a fifty-two week low of $42.14 and a fifty-two week high of $65.09.

Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.08. The company had revenue of $383.60 million during the quarter, compared to the consensus estimate of $373.29 million. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. Integra Lifesciences’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 EPS. Analysts forecast that Integra Lifesciences Holdings Corp will post 2.73 EPS for the current year.

In related news, COO Glenn Coleman sold 3,500 shares of the company’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $57.50, for a total value of $201,250.00. Following the completion of the transaction, the chief operating officer now owns 35,194 shares of the company’s stock, valued at approximately $2,023,655. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Peter J. Arduini sold 250,000 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $60.55, for a total transaction of $15,137,500.00. Following the completion of the transaction, the chief executive officer now directly owns 433,017 shares of the company’s stock, valued at approximately $26,219,179.35. The disclosure for this sale can be found here. Insiders sold a total of 887,921 shares of company stock valued at $54,121,075 in the last ninety days. 4.50% of the stock is currently owned by insiders.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Recommended Story: What does earnings per share mean?

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.